Taken together, the morphological changes observed by us after repetitive fluoxetine administration, consistent with a GluN2B subunit reduction in several forebrain areas, may have promising applications in brain disorders beyond depression. The gene discussed is GRIN2B; the disease is depressive symptom measurement.